pSivida implant meets primary endpoint in late-stage trial

pSivida (NSDQ:PSDV) touted data from the 2nd Phase III trial of its Durasert 3-year treatment for posterior segment uveitis. The company reported that the trial, which followed patients for 3 years, met its primary endpoint of prevention of recurrence of posterior uveitis at 6 months.

In the 153-patient trial, 21.8% of Durasert-treated patients had a recurrence compared to 53.8% of patients in the sham group.

Get the full story at our sister site, Drug Delivery Business News.

The post pSivida implant meets primary endpoint in late-stage trial appeared first on MassDevice.

from MassDevice http://ift.tt/2saumUm